SCHEMBL5639244

SCHEMBL5639244

O=C(O)N[C@H]1CCCCN(C(=O)NS(=O)(=O)c2ccccc2)C1=O

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ F2 P00734 3/20 0.41
▸ PRSS1 P07477 3/20 0.41
▸ PRSS2 P07478 2/20 0.41
▸ PRSS3 P35030 2/20 0.41
▸ HRH1 P35367 1/20 0.40
▸ CCR3 P51677 1/20 0.40
▸ KCNH2 Q12809 1/20 0.40
▸ F10 P00742 1/20 0.40
▸ MME P08473 1/20 0.40
▸ ACE P12821 1/20 0.40
▸ ALOX15 P16050 1/20 0.39
▸ PPARG P37231 1/20 0.39
▸ MMP2 P08253 1/20 0.39
▸ MMP9 P14780 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ ADORA3 P0DMS8 1/20 0.38
▸ GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5638804 0.83 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2F2PRSS1PRSS2
SCHEMBL5637813 0.80 RAB9A (0.48) ALDH1A1SMN1; SMN2TSHRGAA
SCHEMBL5638887 0.78 EPHX2 (0.46) ALDH1A1SMN1; SMN2MMP2GAA
SCHEMBL5638525 0.77 ALDH1A1 (0.64) ALDH1A1SMN1; SMN2MMEACETSHR
SCHEMBL5641964 0.75 FPR2 (0.48) ALDH1A1GAA
SCHEMBL5640381 0.74 ALDH1A1 (0.50) ALDH1A1MMEACE
SCHEMBL10837093 0.74 ALDH1A1 (0.46) ALDH1A1KCNH2MMP2MMP9ADORA3
SCHEMBL10837099 0.74 ALDH1A1 (0.46) ALDH1A1KCNH2MMP2MMP9ADORA3
SCHEMBL5639998 0.73 NPY1R (0.40) MMEACE
SCHEMBL5637096 0.72 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220856-B2 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2007-05-22 — — US disclosed
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2004-04-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists CCR5, CXCR3, CCR2 ALDH1A1 1286/4885SMN1; SMN2 4121/4885F2 4543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback